Ros Deegan, OMass Therapeutics CEO
October 15, 2026 02:00 AM EDT
OMass Therapeutics collects $310M to chase Neurocrine, Vertex in genetic adrenal disorder
An Oxford-based drug developer has raised one of the largest private financings for a UK biotech in recent years as it seeks to follow in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source
ENDPOINTS CAREERS